At the news
? BULLISHIMPACT 7/10 6-K filed Jul 27, 2026 at 06:56 ET
AstraZeneca announced positive Phase III results for its wholly owned ADC, Sone-Ve (sonesitatug vedotin), demonstrating a statistically significant and highly clinically meaningful improvement in overall survival (OS) in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers. This is the first pivotal readout from AZN's wholly owned ADC portfolio and the first Phase III trial to show an OS benefit with an anti-CLDN18.2 ADC in this setting, potentially expanding the treatable population to ~60% of patients with CLDN18.2 expression ≥25%. The PFS endpoint showed a trend but did not reach statistical significance, though the OS win in a large unmet need is a major positive for AZN's oncology pipeline.
- Sone-Ve met the dual primary endpoint of OS in 3rd and later-line treatment and the key secondary endpoint of OS in the overall 2nd and later-line population (statistically significant, highly clinically meaningful)
- PFS by BICR showed a trend toward improvement but did not reach statistical significance
- First Phase III trial to show OS benefit with an anti-CLDN18.2 ADC in gastric/GEJ cancers
- Trial included patients with CLDN18.2 expression on ≥25% of tumor cells, expanding the potential addressable population to ~60% of patients
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access